米妥昔单抗索拉夫坦新联合贝伐珠单抗治疗铂耐药卵巢癌的Ib期研究
该Ib期研究评估了叶酸受体α(FRα)靶向抗体药物偶联物(ADC)米妥昔单抗索拉夫坦新联合贝伐珠单抗在FRα阳性铂耐药卵巢癌患者中的安全性和临床活性。联合方案耐受良好,确认客观缓解率(ORR)为39%,中位无进展生存期(PFS)为6.9个月;在贝伐珠单抗初治、既往治疗线数较少且FRα中/高表达亚组中活性尤为突出。
要点
- 联合方案在铂耐药卵巢癌中耐受良好,常见不良事件为腹泻、视物模糊、恶心和乏力。
- 总体确认ORR为39%,中位PFS为6.9个月。
- 贝伐珠单抗初治、既往1-2线治疗且FRα中/高表达亚组ORR达56%,中位缓解持续时间12个月,PFS 9.9个月。
核心结论
- 米妥昔单抗索拉夫坦新联合贝伐珠单抗在铂耐药复发性卵巢癌患者中耐受良好,疗效指标优于贝伐珠单抗联合标准化疗的历史报告。
主要发现
- 不良事件多为轻至中度(≤2级),最常见治疗相关毒性为腹泻、视物模糊、恶心和乏力。
- 观察到6例肺炎(9%;均为1或2级),为特别关注的不良事件。
- 确认ORR为39%,包括5例完全缓解和21例部分缓解,中位PFS为6.9个月。
- 在贝伐珠单抗初治、既往1-2线治疗且FRα中/高表达亚组(n=16)中,ORR为56%,中位缓解持续时间12个月,PFS为9.9个月。
关键数值与推荐
- 米妥昔单抗索拉夫坦新剂量为6 mg/kg(调整理想体重),贝伐珠单抗剂量为15 mg/kg,每3周一次。
- 入组要求FRα免疫组化阳性,允许既往贝伐珠单抗暴露。
- 患者既往治疗中位线数为3线(范围1-8)。
临床怎么用
- 对于FRα阳性铂耐药卵巢癌,尤其贝伐珠单抗初治、既往治疗线数较少且FRα中/高表达者,可考虑米妥昔单抗索拉夫坦新联合贝伐珠单抗。
- 治疗期间需监测肺炎等特别关注的不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and clinical activity of mirvetuximab soravtansine, an antibody-drug conjugate comprising a humanized anti-folate receptor alpha (FRα) monoclonal antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent, in combination with bevacizumab in patients with FRα-positive, platinum-resistant ovarian cancer. METHODS: Patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer were administered mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) and bevacizumab (15 mg/kg) once every 3 weeks. Eligibility included FRα positivity by immunochemistry and prior bevacizumab exposure was permitted. Adverse events, tumor response, and progression-free survival (PFS) were determined. RESULTS: Sixty-six patients, with a median of 3 prior lines of therapy (range, 1-8), received the combination of mirvetuximab soravtansine and bevacizumab at full dosing during the escalation and expansion stages of the study. Adverse events were generally mild-to-moderate (≤grade 2) with diarrhea, blurred vision, nausea, and fatigue being the most common treatment-related toxicities. Six cases of pneumonitis (9%; all grade 1 or 2), an adverse event of special interest, were observed. The confirmed objective response rate (ORR) was 39%, including 5 complete responses and 21 partial responses, and the median PFS was 6.9 months. The combination was particularly active in the subset of patients (n = 16) who were bevacizumab-naïve, less heavily pretreated (1-2 prior lines), and whose tumors exhibited medium/high FRα expression (ORR, 56% with a median duration of response of 12 months; PFS, 9.9 months). CONCLUSION: The combination of mirvetuximab soravtansine with bevacizumab is well tolerated in patients with platinum-resistant, recurrent ovarian cancer. The encouraging efficacy measures compare favorably to reported outcomes for bevacizumab combined with standard chemotherapy in similar patient populations.
引用
- O'Malley DM, Matulonis UA, Birrer MJ, et al. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020. PMID: 32081463. doi:10.1016/j.ygyno.2020.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。